sana biotechnology news

type 1 diabetes, Sana

SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results from a potentially groundbreaking type 1 diabetes (T1D) study of its experimental cell therapy,

Business Insider · 2d

Sana Biotechnology up 285% afterhours following type 1 diabetes study data

EST Sana Biotechnology (SANA) up 285% afterhours following type 1 diabetes study dataStay Ahead of the Market:Discover outperforming

MarketWatch · 2d

Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection,

Hosted on MSN1d

Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In Excitement

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes ...

bovnews4h

Sana Biotechnology Inc (SANA) Stock: A Deeper Look at Its True Potential

Sana Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -16.99%. The profit margin, also known as the revenue ratio or gross profit ratio ...

FierceBiotech2d

Sana’s cell therapy may be ‘transformative cure’ for type 1 diabetes: analysts

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Sana Biotechnology’s Hypoimmune Platform: A Transformative Breakthrough in Type 1 Diabetes Treatment and Beyond

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target ...

bovnews2d

Sana Biotechnology’s (SANA) Revolutionary Breakthrough Sends Stock Soaring

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...

Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology’s Promising UP421 Results and Potential Upside: A Buy Rating Affirmed

Analyst Vikram Purohit from Morgan Stanley maintained a Buy rating on Sana Biotechnology (SANA – Research Report) and keeping the price target ...

BioPharma Dive1d

Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Sana Biotechnology Shares Spike Following Successful Transplantation

Shares of Sana Biotechnology surged after the company released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The stock more than tripled, up 265% ...

Hosted on MSN1d

TD Cowen Upgrades Sana Biotechnology (SANA)

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Hold to ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results